Gruberg L, Mintz G S, Mehran R, Gangas G, Lansky A J, Kent K M, Pichard A D, Satler L F, Leon M B
Cardiac Catheterization Laboratory, Washington Hospital Center, DC 20010, USA.
J Am Coll Cardiol. 2000 Nov 1;36(5):1542-8. doi: 10.1016/s0735-1097(00)00917-7.
Acute deterioration in renal function is a recognized complication after coronary angiography and intervention.
The goal of this study was to determine the impact on acute and long-term mortality and morbidity of contrast-induced deterioration in renal function after coronary intervention.
We studied 439 consecutive patients who had a baseline serum creatinine > or = 1.8 mg/dL (159.1 /micromol/L) who were not on dialysis who underwent percutaneous coronary intervention in a tertiary referral center. All patients were hydrated before the procedure, and almost all received ioxaglate meglumine; 161 (37%) patients had an increase in serum creatinine > or = 25% within 48 h or required dialysis and 278 (63%) did not. In-hospital and out-of-hospital clinical events (death, myocardial infarction, repeat revascularization) were assessed by source documentation.
Independent predictors of renal function deterioration were left ventricular ejection fraction (p = 0.02) and contrast volume (p = 0.01). In-hospital mortality was 14.9% for patients with further renal function deterioration versus 4.9% for patients with no creatinine increase (p = 0.001); other complications were also more frequent. Thirty-one patients required hemodialysis; their in-hospital mortality was 22.6%. Four patients were discharged on chronic dialysis. The cumulative one-year mortality was 45.2% for those who required dialysis, 35.4% for those who did not require dialysis and 19.4% for patients with no creatinine increase (p = 0.001). Independent predictors of one-year mortality were creatinine elevation (p = 0.0001), age (p = 0.03) and vein graft lesion location (p = 0.08).
For patients with pre-existing renal insufficiency, renal function deterioration after coronary intervention is a marker for poor outcomes. This is especially true for patients who require dialysis.
肾功能急性恶化是冠状动脉造影和介入治疗后公认的并发症。
本研究的目的是确定冠状动脉介入治疗后造影剂所致肾功能恶化对急性和长期死亡率及发病率的影响。
我们研究了439例在三级转诊中心接受经皮冠状动脉介入治疗的患者,这些患者基线血清肌酐≥1.8mg/dL(159.1μmol/L)且未接受透析治疗。所有患者在手术前均进行了水化,几乎所有患者均接受了碘克沙醇葡甲胺;161例(37%)患者在48小时内血清肌酐升高≥25%或需要透析,278例(63%)患者未出现这种情况。通过原始记录评估住院期间和出院后的临床事件(死亡、心肌梗死、再次血管重建)。
肾功能恶化的独立预测因素是左心室射血分数(p = 0.02)和造影剂用量(p = 0.01)。肾功能进一步恶化的患者住院死亡率为14.9%,而肌酐未升高的患者为4.9%(p = 0.001);其他并发症也更常见。31例患者需要血液透析;他们的住院死亡率为22.6%。4例患者出院后接受慢性透析。需要透析的患者1年累计死亡率为45.2%,不需要透析的患者为35.4%,肌酐未升高的患者为19.4%(p = 0.001)。1年死亡率的独立预测因素是肌酐升高(p = 0.0001)、年龄(p = 0.03)和静脉桥血管病变部位(p = 0.08)。
对于已有肾功能不全的患者,冠状动脉介入治疗后肾功能恶化是预后不良的标志。对于需要透析的患者尤其如此。